In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI

Af­ter run­ning through a lengthy stretch watch­ing the mar­ket down­shift ex­pec­ta­tions of its can­cer pipeline, Grit­stone On­col­o­gy has erupt­ed with a quick set of ad­vances …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER